SanBio Co (SanBio Co) Construction In Progress : $0.00 Mil (As of Apr. 2024)

View and export this data going back to 2015. Start your Free Trial

What is SanBio Co Construction In Progress?

SanBio Co's quarterly construction in progress increased from Oct. 2023 ($0.00 Mil) to Jan. 2024 ($0.06 Mil) but then declined from Jan. 2024 ($0.06 Mil) to Apr. 2024 ($0.00 Mil).

SanBio Co's annual construction in progress increased from Jan. 2022 ($0.00 Mil) to Jan. 2023 ($0.04 Mil) and increased from Jan. 2023 ($0.04 Mil) to Jan. 2024 ($0.06 Mil).

SanBio Co Construction In Progress Historical Data

The historical data trend for SanBio Co's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SanBio Co Construction In Progress Chart

SanBio Co Annual Data

Trend

Jan15

Jan16

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Jan24

Construction In Progress

Get a 7-Day Free Trial

0.51

0.04

0.06

SanBio Co Quarterly Data
	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24
Construction In Progress	Get a 7-Day Free Trial															-	-	-	0.06	-

SanBio Co Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

SanBio Co (SanBio Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SanBio Co Ltd (OTCPK:SNBIF) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

4592:Japan

Address

8-1 Street Luke Tower 32nd Floor, Akashi-cho, Chuo-ku, Tokyo, JPN, 104-0044

Website

https://www.sanbio.com

SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.